Corrected: Westlake targets $450M for Seidenberg's next life sciences fund

Kyle LaHucik

Senior Reporter

Life sciences VC firm Westlake Village BioPartners is ready to restock its capital reserves shortly after its success with bringing portfolio company Acelyrin to one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Corrected: Westlake targets $450M for Seidenberg's next life sciences fund

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Cor­rect­ed: West­lake tar­gets $450M for Sei­den­berg's next life sci­ences fund

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Corrected: Westlake targets $450M for Seidenberg's next life sciences fund